First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 297 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... January 28, 2022 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers September 14, 2024 Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... October 19, 2021 Load more HOT NEWS Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... Veteran Avoided The Barber For 6 Years After He Left The...
